Shasqi

🎉 Big news! We're thrilled to announce 6 presentations across two leading scientific conferences next week.    World ADC Event Series (San Diego):  👉 Two speaker sessions, featuring our CEO & Founder, José M. Mejía Oneto, and VP of Research Travis Biechele discussing approaches to overcome off-target toxicities associated with ADCs and sharing data from Shasqi’s novel Click Activated Protodrugs Against Cancer (CAPAC®) technology.  👉 Two posters sharing more details on CAPAC and data from our pipeline assets.  39th Annual Society for Immunotherapy of Cancer (SITC) Meeting:  👉 Two groundbreaking posters including first-in-human data from our Phase 1/2a sarcoma trial and exciting preclinical results demonstrating immune activation associated with MMAE administration via CAPAC.    We’re excited to continue existing conversations and start new ones around partnering our CAPAC pre-targeting technology. Interested? Reach out to Mukul Agarwal, drop a comment below or stop by at either conference!    Details 👇 https://lnkd.in/gkh8RAw9   #WorldADC #SITC2024 #SITC24 #biotech #innovation

Ready when you are! Come find Jesse McFarland and Michael Zakharian are excited to talk all things pre-targeting. Want to catch up with José or Travis? They'll be there! 👉 Poster number 76 "Pre-targeting with in vivo Click Chemistry Enables Preferential Drug Exposure in Tumors versus Normal Tissues" 👉 Poster number 77 "CEACAM5 is an Ideal Target for Click Chemistry Enabled Pre-Targeting" #WorldADC #ADCs #biotech #innovation World ADC Event Series Hanson Wade Group

We’ve officially kicked off the main conference days at the 15th World ADC San Diego! Today’s panel session, “Moving the Needle Forward in 2025 & Beyond,” featured industry leaders from Pfizer, Johnson & Johnson, AstraZeneca, Ipsen, and Iksuda Therapeutics. The panel was moderated by Jeffrey Settleman #WorldADCSanDiego #ADC #biopharma #drugdiscovery #innovation

At #WorldADC and intrigued by precise tumor targeting?   Join us at our two poster presentations showcasing how in vivo click chemistry is redefining therapeutic windows in cancer treatment.     Discover how our pre-targeting approach achieves increased tumor-targeted drug exposure while sparing healthy tissues. Meet our team and explore the future of targeted therapeutics.   #clickchemistry #adc #drugdevelopment #biotech #innovation #research 

Thank you to everyone who attended Travis’ session at #WorldADC this morning! We're excited to have shared our thoughts on how pre-targeting with our CAPAC platform can limit off-target toxicities and improve patient benefit.    We look forward to more great discussions throughout the week - catch our poster session tomorrow evening! 🔬 2 Poster Presentations with Jesse McFarland and Michael Zakharian: Tuesday, Nov 5 - 6:30pm PST 📅 Shasqi CEO José M. Mejía Oneto speaking session: Wednesday, Nov 6 - 12:45pm PST    #biotech #research #innovation #adc

The Shasqi team have arrived in San Diego! Mukul, Travis, José, Michael, and Jesse are excited to join colleagues in the targeted therapy space over the next few days. Come find us to learn more about our technology👇 📅 Speaker Session: Wednesday, Nov 6 - 12:45pm PST  🔬 Poster Presentations: Tuesday, Nov 5 - 6:30pm PST #WorldADC #ADCs #biotech

Get ready World ADC Event Series for a deep dive into Shasqi’s novel pre-targeting CAPAC platform, an approach that can overcome the off-target toxicities associated with ADCs. Find our VP of Research, Travis Biechele, PhD at the 5th Toxicity Day track today, presenting at 10:30am. #biotech #WorldADC #innovation

Last week was National Chemistry Week and we took the opportunity to ask members of the Shasqi research team Jesse McFarland and Nathan A. Yee, PhD what they love most about chemistry.    #ClickwithShasqi #chemistry #ACS_NCW 

As you may have seen, José M. Mejía Oneto has been at the EORTC - European Organisation for Research and Treatment of Cancer- National Cancer Institute (NCI)- American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics this week. Great conversations and questions, hearing what is coming next for targeted therapies and what are the critical challenges in the field from the best in the field are more energizing than coffee! Some highlights: Yesterday’s morning session: “Fine-tuning the use of ADC’s to treat cancer” featuring Paolo Tarantino and Raffaele Colombo who gave a powerful presentation (congrats on the publication of your recent, comprehensive review in Cancer Research). The session also featured key insights from Prof Barbara Pistilli and Prof Giuseppe Curigliani on the interaction between IO therapies and ADCs. The Chemistry in Cancer research Town Hall which included a fascinating presentation by Matthew Levengood from Pfizer on potential improvements to MMAE payloads. We want to thank the organizing committee and the chairs for selecting our work showcasing “in vivo click chemistry to enable pre targeting for ADCs and targeted radiopharmaceuticals” for a late breaking abstract (P521 for those still in Barcelona). We've enjoyed some great questions and conversations. You can find the poster at the link 👉 https://lnkd.in/ggJkQx9C Next on our list: World ADC Event Series in San Diego as well as the 39th Annual Society for Immunotherapy of Cancer (SITC) meeting coming up in November. We look forward to seeing you there!

We had a great start to the EORTC - European Organisation for Research and Treatment of Cancer- National Cancer Institute (NCI)- American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics.    Find our presented poster here: https://lnkd.in/ggJkQx9C and learn more about why CAPAC is designed to improve therapeutic index of potent cytotoxic drugs and radioisotopes by dramatically reducing the exposure and toxicity to healthy cells. #ENASymp24 #biotech #research #innovation